Drug intelligence / Profile preview

KR25102

Development stage: Phase 1
Lead developer: Qingfeng Pharmaceutical Group
Modality: Small Molecules

Overview

KR25102 is a preclinical-stage drug candidate being developed by Jiangxi Kvvit Pharmaceutical, a subsidiary of the Qingfeng Pharmaceutical Group. As of early 2024, the compound is in the Preclinical Candidate (PCC) stage of development. Publicly available information regarding its specific molecular target, mechanism of action, and primary therapeutic indication is currently limited; however, it is categorized within the company's pipeline under therapeutic areas that include the central nervous system (CNS) and other specialized indications. Based on the developer's typical pipeline for this code series, it is likely a small molecule therapeutic.

Beyond the preview

Go deeper on KR25102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KR25102.

Explore the full profile